PapersFlow Research Brief
Renal cell carcinoma treatment
Research Guide
What is Renal cell carcinoma treatment?
Renal cell carcinoma treatment encompasses surgical interventions like nephron-sparing surgery, targeted therapies such as sunitinib, sorafenib, temsirolimus, and axitinib, and immunotherapies including nivolumab, ipilimumab, and pembrolizumab, aimed at improving survival in localized and metastatic disease.
The field includes 86,905 papers on renal cell carcinoma treatment modalities, prognostic factors, molecular characterization, nephron-sparing surgery, immunotherapy, genetic mutations, and clinical guidelines. Motzer et al. (2015) showed nivolumab extended overall survival compared to everolimus in previously treated advanced renal-cell carcinoma patients, with fewer grade 3 or 4 adverse events. Escudier et al. (2007) demonstrated sorafenib prolonged progression-free survival versus placebo in advanced clear-cell renal-cell carcinoma after prior therapy.
Topic Hierarchy
Research Sub-Topics
Immune Checkpoint Inhibitors in Renal Cell Carcinoma
This sub-topic examines the efficacy, safety profiles, and resistance mechanisms of PD-1/PD-L1 and CTLA-4 inhibitors such as nivolumab and ipilimumab in treating advanced RCC. Researchers investigate combination therapies, biomarker identification, and immune-related adverse events in clinical trials and real-world data.
Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
This area focuses on multi-targeted TKIs like sunitinib, sorafenib, and axitinib, evaluating their anti-angiogenic effects, dosing strategies, and comparative effectiveness against other therapies. Studies analyze progression-free survival, toxicity, and sequencing in first-line and subsequent lines of treatment.
Nephron-Sparing Surgery in Renal Cell Carcinoma
Researchers study partial nephrectomy techniques, including robotic and laparoscopic approaches, for localized RCC, assessing oncologic outcomes, renal function preservation, and patient selection criteria. Investigations include perioperative complications and long-term survival compared to radical nephrectomy.
Molecular Subtypes of Clear Cell Renal Cell Carcinoma
This sub-topic explores genomic and transcriptomic profiling, including VHL mutations and mTOR pathway alterations, to classify ccRCC subtypes for precision medicine. Researchers develop molecular classifiers and correlate them with therapeutic responses and prognosis.
Biomarkers for Prognosis in Renal Cell Carcinoma
Studies identify and validate circulating, tissue-based, and imaging biomarkers like PD-L1 expression, neutrophil-lymphocyte ratio, and gene signatures for predicting RCC outcomes. Researchers assess their utility in risk stratification and treatment selection across stages.
Why It Matters
Treatments like nivolumab have improved survival in advanced renal-cell carcinoma, as Motzer et al. (2015) reported longer overall survival than everolimus in the CheckMate 025 trial (ClinicalTrials.gov NCT01668784). Combinations such as nivolumab plus ipilimumab outperformed sunitinib in intermediate- and poor-risk patients, with higher overall survival and objective response rates in the CheckMate 214 trial (Motzer et al., 2018). Pembrolizumab plus axitinib yielded significantly longer progression-free survival and higher response rates than sunitinib in untreated advanced cases (Rini et al., 2019). Sunitinib increased progression-free survival over interferon alfa in metastatic disease (Motzer et al., 2007), while temsirolimus improved survival in poor-prognosis metastatic patients versus interferon alfa (Hudes et al., 2007). These therapies provide options across risk groups, influencing clinical guidelines like the EAU update (Ljungberg et al., 2015).
Reading Guide
Where to Start
'Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma' (Motzer et al., 2015) first, as it directly compares immunotherapy to standard targeted therapy, showing survival gains and safety data in advanced disease.
Key Papers Explained
Motzer et al. (2007) 'Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma' established sunitinib's superiority in progression-free survival, setting a benchmark. Escudier et al. (2007) 'Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma' and Hudes et al. (2007) 'Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma' expanded targeted options post-failure. Motzer et al. (2015) 'Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma' introduced immunotherapy advantages. Motzer et al. (2018) 'Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma' and Rini et al. (2019) 'Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma' built on these with superior combinations in frontline settings.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
EAU Guidelines on Renal Cell Carcinoma: 2014 Update (Ljungberg et al., 2015) synthesize surgical and systemic approaches. Molecular data from Wheeler et al. (2013) 'Comprehensive molecular characterization of clear cell renal cell carcinoma' inform resistance mechanisms. No recent preprints or news available.
Papers at a Glance
Frequently Asked Questions
What survival benefits did nivolumab provide over everolimus?
In previously treated advanced renal-cell carcinoma patients, nivolumab extended overall survival compared to everolimus. Fewer grade 3 or 4 adverse events occurred with nivolumab (Motzer et al., 2015, 'Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma'). This was from the CheckMate 025 trial (NCT01668784).
How did sunitinib compare to interferon alfa?
Sunitinib lengthened progression-free survival and raised response rates over interferon alfa in metastatic renal-cell carcinoma patients. Results came from trials NCT00098657 and NCT00083889 (Motzer et al., 2007, 'Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma').
What are key treatments in EAU guidelines?
EAU Guidelines on Renal Cell Carcinoma: 2014 Update cover treatment modalities including surgery, targeted therapies, and immunotherapy (Ljungberg et al., 2015). They address prognostic factors and clinical management.
What molecular insights exist for clear cell renal cell carcinoma?
Comprehensive molecular characterization details genomic features of clear cell renal cell carcinoma. It identifies mutations and pathways relevant to treatment response (Wheeler et al., 2013, 'Comprehensive molecular characterization of clear cell renal cell carcinoma').
What risks come with immune checkpoint inhibitors?
Immune checkpoint inhibitors like anti-CTLA-4 and anti-PD-1 can cause adverse renal effects. These include risks from engaging the immune system against tumors (Wanchoo et al., 2017, 'Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review').
Open Research Questions
- ? How can molecular profiles from comprehensive characterization predict responses to immunotherapy combinations like nivolumab plus ipilimumab?
- ? What strategies mitigate renal adverse effects of checkpoint inhibitors in renal cell carcinoma patients?
- ? Which patient subgroups benefit most from pembrolizumab plus axitinib versus sunitinib?
- ? How do targeted agents like temsirolimus integrate with current immunotherapy standards?
- ? What prognostic factors refine risk stratification beyond intermediate and poor categories?
Recent Trends
The field encompasses 86,905 papers with no specified 5-year growth rate.
Immunotherapy combinations like nivolumab plus ipilimumab (Motzer et al., 2018) and pembrolizumab plus axitinib (Rini et al., 2019) advanced beyond single-agent targeted therapies such as sunitinib (Motzer et al., 2007).
No recent preprints or news in the last 12 months reported.
Research Renal cell carcinoma treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Renal cell carcinoma treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers